We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GenVec, Inc. announced that it has received a $430,000 Phase I Small Business Innovation Research award from the National Institute of Allergy and Infectious Diseases Biodefense Program to support the company's efforts to develop novel adenovector-based vaccine technology.
Emergent BioSolutions Inc., a privately held biopharmaceutical company, announced that the United States Department of Homeland Security (DHS) has granted the company's application for designation and certification of BioThrax (Anthrax Vaccine Adsorbed) as a "qualified anti-terrorism technology" under the "Support Anti- Terrorism by Fostering Effective Technology Act" (SAFETY Act).
CytRx Corporation announced that it has received $24.5 million in a non-dilutive royalty agreement with the privately-funded ALS Charitable Remainder Trust to fund continued development of the Company's lead small molecule drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
PDL BioPharma, Inc. announced that Roche has discontinued its involvement in the development of daclizumab in asthma, which both companies had been co-developing since 2004.
The Food and Drug Administration proposed a ban Tuesday on over-the-counter sales of skin-lightening products, saying possible health risks cannot justify their being sold without a prescription.
The UK's National Institute for Health and Clinical Excellence (NICE) does not believe that two cancer drugs, Roche Products' Avastin and Merck Pharmaceuticals' Erbitux, should be used in treating metastatic colorectal cancer, a recent draft report says.
Roche's acne drug Accutane, already known to cause birth defects, may raise the risk for patients to develop other health problems, according to a study published in the August issue of Archives of Dermatology.
The FDA's advisory committee system is slanted toward approval of drugs, even when there are significant concerns about those products' safety, an activist group concludes in an Aug. 28 report.